Target intelligence / Profile preview

Protein EFR3 homolog B (EFR3B)

Target
EFR3B
Molecular classification
Other (Peripheral membrane protein; Armadillo-like repeat protein)
01

Overview

Protein EFR3 homolog B (EFR3B) is a peripheral membrane protein found in humans that plays a crucial role in anchoring the phosphatidylinositol 4-kinase alpha (PI4KA) complex to the plasma membrane[1][3]. This anchoring is essential for the synthesis and regulation of phosphatidylinositol 4-phosphate (PtdIns4P), a lipid critical for membrane identity, signaling, and trafficking[1][2][3]. EFR3B belongs to the armadillo (ARM)-repeat superfamily of proteins, forming superhelical rod-like structures that facilitate protein-protein interactions[1]. Its N-terminal region is palmitoylated, which determines plasma membrane localization and modulates its association with both membrane rafts and TMEM150A[1][2]. EFR3B is one of two paralogs in mammals, the other being EFR3A; both share core functions but may differ in regulatory details—particularly phosphorylation and potential tissue distribution[1][2]. Disruption of EFR3B or its associated complex partners can affect GPCR signaling, phosphoinositide signaling, and has been associated with disease settings such as cancer, neurological, and cardiovascular disorders, albeit its direct role as a therapeutic target is not established[1][2][3]. EFR3B’s principal known molecular function is the stable recruitment and localization of the PI4KA complex alongside TTC7(FAM126) proteins at the plasma membrane, a process critical for maintaining phosphoinositide homeostasis[1][2][3]. Key points: - EFR3B is not itself a receptor, enzyme, or traditional drug target, but a scaffold protein critical for membrane localization of kinase complexes and thus proper signal transduction[1][2][3]. - Mutations or dysfunctions in EFR3B or its complex may contribute to disease phenotypes, mostly indirectly via disruption of cellular signaling[1][2]. - No drugs are currently known to directly interact with EFR3B, nor is there evidence of EFR3B acting as a biomarker or being associated with specific safety/therapeutic concerns[3].

Other names
EFR3BKIAA0953FLJ37871protein EFR3 homolog B
02

Biological functions

Plasma membrane anchoring of the phosphatidylinositol 4-kinase alpha (PI4KA) complexRegulation of phosphatidylinositol 4-phosphate (PtdIns4P) synthesisRegulation of phosphoinositide metabolism at the plasma membraneProtein-protein interactions affecting membrane microdomain organizationScaffold for signal transduction complexes
03

Disease associations

CancerCardiovascular diseaseNeurodevelopmental/neurological disordersOther (based on association with PI4KA and its complex partners)

Beyond the preview

Go deeper on Protein EFR3 homolog B (EFR3B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein EFR3 homolog B (EFR3B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call